Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled Study in Healthy Volunteers to Determine the Safety and Tolerability of Single, Ascending Subcutaneous Doses of Sevuparin

Trial Profile

A Double-blind, Placebo-controlled Study in Healthy Volunteers to Determine the Safety and Tolerability of Single, Ascending Subcutaneous Doses of Sevuparin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevuparin (Primary)
  • Indications Falciparum malaria; Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Modus Therapeutics
  • Most Recent Events

    • 15 Jul 2019 Status changed from recruiting to completed.
    • 25 Nov 2018 New trial record
    • 07 Nov 2018 According to a Modus Therapeutics media release, the company announces that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top